Management of hypertension in chronic kidney disease

Nature Reviews Nephrology

Volumn 11, Issue 9, 2015, Pages 555-563

  Townsend, Raymond R ^a   Taler, Sandra J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; SODIUM;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; AUTOREGULATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DEVICE THERAPY; DIASTOLIC BLOOD PRESSURE; HOME MONITORING; HUMAN; HYPERTENSION; KIDNEY DENERVATION SYSTEM; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTOLIC BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; PRACTICE GUIDELINE;

BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84940452310     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.114     Document Type: Review

References (111)

1. Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825-830 (2013).
2. Muntner, P. et al. Hypertension awareness, treatment, and control in adults with chronic kidney disease: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am. J. Kidney Dis. 55, 441-451 (2009).
3. Bakris, G. L. et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36, 646-661 (2000).
4. Young, J. H. et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 13, 2776-2782 (2002).
5. Palmer, B. F. Hypertension management in patients with chronic kidney disease. Curr. Hypertens. Rep. 10, 367-373 (2008).
6. Rao, M. V., Qiu, Y., Wang, C. & Bakris, G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am. J. Kidney Dis. 51 (Suppl. 2), S30-S37 (2008).
7. Matsushita K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375, 2073-2081 (2010).
8. Ren, Y. et al. Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am. J. Physiol. Renal Physiol. 307, F533-F538 (2014).
9. Rhaleb, N. E., Yang, X. P. & Carretero, O. A. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr. Physiol. 1, 971-993 (2011).
10. Elijovich, F. 20-HETE and salt-sensitivity of blood pressure a novel emerging concept. Am. J. Hypertens. 19, 1181-1182 (2006).
11. Sharma, J. N. & Narayanan, P. The kallikrein-kinin pathways in hypertension and diabetes. Prog. Drug Res. 69, 15-36 (2014).
12. Ito, Y. et al. Norepinephrine responsiveness in patients with borderline hypertension under three different sodium balances. Clin. Exp. Hypertens. A. 11 (Suppl 1), 363-370 (1989).
13. Hovater, M. B. & Sanders, P. W. Effect of dietary salt on regulation of TGF-beta in the kidney. Semin. Nephrol. 32, 269-276 (2012).
14. Koomans, H. A., Roos, J. C., Boer, P., Geyskes, G. G. & Mees, E. J. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4, 190-197 (1982).
15. Esler, M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: The transition from mechanisms to medical management. J. Appl. Physiol. 108, 227-237 (2010).
16. Converse, R. L. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918 (1992).
17. Klein, I. H., Ligtenberg, G., Neumann, J., Oey, P. L., Koomans, H. A. & Blankestijn, P. J. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J. Am. Soc. Nephrol. 14, 3239-3244 (2003).
18. DiBona, G. F. & Kopp, U. C. Neural control of renal function. Physiol. Rev. 77, 75-197 (1997).
19. Kobori, H., Nangaku, M., Navar, L. G. & Nishiyama, A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287 (2007).
20. Conn, J. W. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45, 3-17 (1955).
21. Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068 (1996).
22. Deo, R. et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 64, 103-110 (2014).
23. Briet, M. & Schiffrin, E. L. Vascular actions of aldosterone. J. Vasc. Res. 50, 89-99 (2013).
24. Richter, C. M. Role of endothelin in chronic renal failure-developments in renal involvement. Rheumatology (Oxford) 45 (Suppl 3), iii36-iii38 (2006).
25. Araujo, M. & Wilcox, C. S. Oxidative stress in hypertension: role of the kidney. Antioxid. Redox Signal. 20, 74-101 (2014).
26. Crowley, S. D. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid. Redox Signal. 20, 102-120 (2014).
27. Lee, J. Nitric oxide in the kidney: its physiological role and pathophysiological implications. Electrolyte Blood Press 6, 27-34 (2008).
28. LeLorier, J. et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclooxygenase2 inhibitors in hypertension and kidney disease. Can. J. Cardiol. 18, 1301-1308 (2002).
29. Verdecchia, P. et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24, 793-801 (1994).
30. Shimada, K., Kawamoto, A., Matsubayashi, K. & Ozawa, T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 16, 692-699 (1990).
31. Verdecchia, P., Angeli, F. & Cavallini, C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation 115, 2091-2093 (2007).
32. Kario, K. et al. Sleep pulse pressure and awake mean pressure as independent predictors for stroke in older hypertensive patients. Am. J. Hypertens. 17, 439-445 (2004).
33. Cohen, D. L., Huan, Y. & Townsend, R. R. Home blood pressure monitoring in CKD. Am. J. Kidney Dis. 63, 835-842 (2014).
34. Minutolo, R. et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch. Intern. Med. 171, 1090-1098 (2011).
35. Agarwal, R. & Andersen, M. J. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am. J. Nephrol. 26, 503-510 (2006).
36. Myers, M. G., Godwin, M., Dawes, M., Kiss, A., Tobe, S. W. & Kaczorowski, J. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55, 195-200 (2010).
37. Stergiou, G. S., Parati, G., Asmar, R. & O'Brien, E. Requirements for professional office blood pressure monitors. J. Hypertens. 30, 537-542 (2012).
38. Graves, J. W., Nash, C., Burger, K., Bailey, K. & Sheps, S. G. Clinical decision-making in hypertension using an automated (BpTRU) measurement device. J. Hum. Hypertens. 17, 823-827 (2003).
39. Myers, M. G., Valdivieso, M., Kiss, A. & Tobe, S. W. Comparison of two automated sphygmomanometers for use in the office setting. Blood Press. Monit. 14, 45-47 (2009).
40. Myers, M. G. & Godwin, M. Automated office blood pressure. Can. J. Cardiol. 28, 341-346 (2012).
41. Wolk, R., Shamsuzzaman, A. S. & Somers, V. K. Obesity, sleep apnea, and hypertension. Hypertension 42, 1067-1074 (2003).
42. Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825-830 (2013).
43. Muntner, P. et al. Hypertension awareness, treatment, and control in adults with chronic kidney disease: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am. J. Kidney Dis. 55, 441-451 (2009).
44. Bakris, G. L. et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36, 646-661 (2000).
45. Young, J. H. et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 13, 2776-2782 (2002).
46. Palmer, B. F. Hypertension management in patients with chronic kidney disease. Curr. Hypertens. Rep. 10, 367-373 (2008).
47. Rao, M. V., Qiu, Y., Wang, C. & Bakris, G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am. J. Kidney Dis. 51 (Suppl. 2), S30-S37 (2008).
48. Matsushita K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375, 2073-2081 (2010).
49. Ren, Y. et al. Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am. J. Physiol. Renal Physiol. 307, F533-F538 (2014).
50. Rhaleb, N. E., Yang, X. P. & Carretero, O. A. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr. Physiol. 1, 971-993 (2011).
51. Elijovich, F. 20-HETE and salt-sensitivity of blood pressure a novel emerging concept. Am. J. Hypertens. 19, 1181-1182 (2006).
52. Sharma, J. N. & Narayanan, P. The kallikrein-kinin pathways in hypertension and diabetes. Prog. Drug Res. 69, 15-36 (2014).
53. Ito, Y. et al. Norepinephrine responsiveness in patients with borderline hypertension under three different sodium balances. Clin. Exp. Hypertens. A. 11 (Suppl 1), 363-370 (1989).
54. Hovater, M. B. & Sanders, P. W. Effect of dietary salt on regulation of TGF-beta in the kidney. Semin. Nephrol. 32, 269-276 (2012).
55. Koomans, H. A., Roos, J. C., Boer, P., Geyskes, G. G. & Mees, E. J. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4, 190-197 (1982).
56. Esler, M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: The transition from mechanisms to medical management. J. Appl. Physiol. 108, 227-237 (2010).
57. Converse, R. L. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918 (1992).
58. Klein, I. H., Ligtenberg, G., Neumann, J., Oey, P. L., Koomans, H. A. & Blankestijn, P. J. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J. Am. Soc. Nephrol. 14, 3239-3244 (2003).
59. DiBona, G. F. & Kopp, U. C. Neural control of renal function. Physiol. Rev. 77, 75-197 (1997).
60. Kobori, H., Nangaku, M., Navar, L. G. & Nishiyama, A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287 (2007).
61. Conn, J. W. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45, 3-17 (1955).
62. Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068 (1996).
63. Deo, R. et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 64, 103-110 (2014).
64. Briet, M. & Schiffrin, E. L. Vascular actions of aldosterone. J. Vasc. Res. 50, 89-99 (2013).
65. Richter, C. M. Role of endothelin in chronic renal failure-developments in renal involvement. Rheumatology (Oxford) 45 (Suppl 3), iii36-iii38 (2006).
66. Araujo, M. & Wilcox, C. S. Oxidative stress in hypertension: role of the kidney. Antioxid. Redox Signal. 20, 74-101 (2014).
67. Crowley, S. D. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid. Redox Signal. 20, 102-120 (2014).
68. Lee, J. Nitric oxide in the kidney: its physiological role and pathophysiological implications. Electrolyte Blood Press 6, 27-34 (2008).
69. LeLorier, J. et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclooxygenase2 inhibitors in hypertension and kidney disease. Can. J. Cardiol. 18, 1301-1308 (2002).
70. Verdecchia, P. et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24, 793-801 (1994).
71. Shimada, K., Kawamoto, A., Matsubayashi, K. & Ozawa, T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 16, 692-699 (1990).
72. Verdecchia, P., Angeli, F. & Cavallini, C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation 115, 2091-2093 (2007).
73. Kario, K. et al. Sleep pulse pressure and awake mean pressure as independent predictors for stroke in older hypertensive patients. Am. J. Hypertens. 17, 439-445 (2004).
74. Cohen, D. L., Huan, Y. & Townsend, R. R. Home blood pressure monitoring in CKD. Am. J. Kidney Dis. 63, 835-842 (2014).
75. Minutolo, R. et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch. Intern. Med. 171, 1090-1098 (2011).
76. Agarwal, R. & Andersen, M. J. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am. J. Nephrol. 26, 503-510 (2006).
77. Myers, M. G., Godwin, M., Dawes, M., Kiss, A., Tobe, S. W. & Kaczorowski, J. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55, 195-200 (2010).
78. Stergiou, G. S., Parati, G., Asmar, R. & O'Brien, E. Requirements for professional office blood pressure monitors. J. Hypertens. 30, 537-542 (2012).
79. Graves, J. W., Nash, C., Burger, K., Bailey, K. & Sheps, S. G. Clinical decision-making in hypertension using an automated (BpTRU) measurement device. J. Hum. Hypertens. 17, 823-827 (2003).
80. Myers, M. G., Valdivieso, M., Kiss, A. & Tobe, S. W. Comparison of two automated sphygmomanometers for use in the office setting. Blood Press. Monit. 14, 45-47 (2009).
81. Myers, M. G. & Godwin, M. Automated office blood pressure. Can. J. Cardiol. 28, 341-346 (2012).
82. Wolk, R., Shamsuzzaman, A. S. & Somers, V. K. Obesity, sleep apnea, and hypertension. Hypertension 42, 1067-1074 (2003).
83. Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall p 83 Lancet 362, 759-766 (2003).
84. Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383-1392 (2014).
85. Krum, H. et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: Analysis of the EMPHASIS-HF study. Circ. Heart Fail. 6, 711-718 (2013).
86. Bomback, A. S. et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am. J. Kidney Dis. 51, 199-211 (2008).
87. Sica, D. A. The kidney and hypertension: causes and treatment. J. Clin. Hypertens. (Greenwich) 10, 541-548 (2008).
88. Ecder, T. et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 21, 98-103 (2001).
89. Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267-2276 (2014).
90. Uzu, T. & Kimura, G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100, 1635-1638 (1999).
91. Bakris, G. L. et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 65, 1991-2002 (2004).
92. Ruggenenti, P., Perna, A., Benini, R. & Remuzzi, G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 9, 2096-2101 (1998).
93. Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173-1181 (2010).
94. Weir, M. R. et al. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 81, 568-576 (2012).
95. Prichard, B. N., Cruickshank, J. M. & Graham, B. R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 10, 366-386 (2001).
96. Taler, S. J., Textor, S. C. & Augustine, J. E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39, 982-988 (2002).
97. Karadsheh, F. & Weir, M. R. Thiazide and thiazide-like diuretics: An opportunity to reduce blood pressure in patients with advanced kidney disease. Curr. Hypertens. Rep. 14, 416-420 (2012).
98. Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131-140 (2006).
99. Yasuda, T. et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens. Res. 36, 240-246 (2013).
100. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proofofprinciple cohort study. Lancet 373, 1275-1281 (2009).
101. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN2 Trial): A randomised controlled trial. Lancet 376, 1903-1909 (2010).
102. Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393-1401 (2014).
103. Hering, D. et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23, 1250-1257 (2012).
104. Gassler, J. P. & Bisognano, J. D. Baroreflex activation therapy in hypertension. J. Hum. Hypertens. 28, 469-474 (2014).
105. Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619-626 (2010).
106. Scheffers, I. J. et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J. Am. Coll. Cardiol. 56, 1254-1258 (2010).
107. Bisognano, J. D. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J. Am. Coll. Cardiol. 58, 765-773 (2011).
108. Wallbach, M. et al. Impact of baroreflex activation therapy on renal function-a pilot study. Am. J. Nephrol. 40, 371-380 (2014).
109. Weber, M. A. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J. Hypertens. 32, 3-15 (2014).
110. Flack, J. M. et al. Management of high blood pressure in Blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56, 780-800 (2010).
111. National Institute for Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care [online], http://www.nice.org.uk/guidance/cg182 (2014).